Non-corticosteroid therapy for the long-term control of asthma

Bibliography

• BUSSE WW, LEMANSKE RF Jr: Asthma. N. Engl. J. Med. (2001) 344:350-362.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention revised (2002). NHLBI/WHO Workshop Report. Bethesda, MD: NIH publication No. 02-3659 (2002).
   Google Scholar
• KELLY HW: What is new with the β2 agonists: issues in the management of asthma. Ann. Pharmacother. (2005) 39:931-938.
   PubMed Web of Science ®Google Scholar
• LIGGETT SB: Update on current concepts of the molecular basis of β2-adrenergic receptor signaling. J. Allergy Clin. Immunol. (2002) 110:S223-S227.
   Google Scholar
• KIPS JC, PAUWELS RA: Long-acting inhaled β(2)-agonist therapy in asthma. Am. J. Respir. Crit. Care Med. (2001) 164:923-932.
   PubMed Web of Science ®Google Scholar
• RABE KF, ATIENZA T, MAGYAR P, LARSSON P, JORUP C, LALLOO UG: Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study. Lancet (2006) 368:744-753.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, FAIRALL L, LOMBARDI DM, ENGLISH R: Budesonide/formoterol and formoterol provide rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir. Res. (2006) 7:13.
   PubMed Web of Science ®Google Scholar
• WALTERS JA, WOOD-BAKER R, WALTERS EH: Long-acting β2-agonists in asthma: an overview of Cochrane systematic reviews. Respir. Med. (2005) 99:384-395.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, BISGAARD H, GODARD PP et al.: Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. (2005) 171:129-136.
   PubMed Web of Science ®Google Scholar
• PAUWELS RA, LOFDAHL CG, POSTMA DS et al.: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. (1997) 337:1405-1411.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am. J. Respir. Crit. Care Med. (2004) 170:836-844.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, ADELROTH E: β2 deja vu. Chest (2006) 129:3-5.
   PubMed Web of Science ®Google Scholar
• NELSON HS, WEISS ST, BLEECKER ER et al.: The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 129:15-26.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R et al.: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. (2001) 164:1392-1397.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, DRAZEN JM, LIGGETT SB et al.: The effect of polymorphisms of the β2 adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. (2000) 162:75-80.
   PubMed Web of Science ®Google Scholar
• TAYLOR DR, DRAZEN JM, HERBISON GP, YANDAVA CN, HANCOX RJ, TOWN GI: Asthma exacerbations during long term β agonist use: influence of β2 adrenoceptor polymorphism. Thorax (2000) 55:762-767.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, CHINCHILLI VM, FORD JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet (2004) 364:1505-1512.
   PubMed Web of Science ®Google Scholar
• TAN S, HALL IP, DEWAR J, DOW E, LIPWORTH B: Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet (1997) 350:995-999.
   PubMed Web of Science ®Google Scholar
• MARTINEZ FD, GRAVES PE, BALDINI M, SOLOMON S, ERICKSON R: Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. (1997) 100:3184-3188.
   PubMed Web of Science ®Google Scholar
• TAYLOR DR, HANCOX RJ, MCRAE W et al.: The influence of polymorphism at position 16 of the β2-adrenoceptor on the development of tolerance to β-agonist. J. Asthma (2000) 37:691-700.
   PubMed Web of Science ®Google Scholar
• LEE DKC, CURRIE GP, HALL IP, LIMA JJ, LIPWORTH BJ: The arginine-16 β2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol. (2003) 57:68-75.
   Web of Science ®Google Scholar
• LIMA JJ, THOMASON DB, MOHAMED MHN, EBERLE LV, SELF TH, JOHNSON JA: Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. (1999) 65:519-525.
   PubMed Web of Science ®Google Scholar
• SALPETER SR, ORMISTON TM, SALPETER EE: Meta-analysis: respiratory tolerance to regular β2-agonist use in patients with asthma. Ann. Intern. Med. (2004) 140:802-813.
   PubMed Web of Science ®Google Scholar
• SALPETER SR, BUCKLEY NS, ORMISTON TM, SALPETER EE: Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann. Intern. Med. (2006) 144:904-912.
   PubMed Web of Science ®Google Scholar
• TATTERSFIELD AE, POSTMA DS, BARNES PJ et al.: Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am. J. Respir. Crit. Care Med. (1999) 160:594-599.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ, AZIZ I: Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest (2000) 117:156-162.
   PubMed Web of Science ®Google Scholar
• VAN DER WOUDE HJ, WINTER TH, AALBERS R: Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate bronchoconstriction during high dose treatment with long acting β2 agonists. Thorax (2001) 56:529-535.
   PubMed Web of Science ®Google Scholar
• JONES SL, COWAN JO, FLANNERY EM, HANCOX RJ, HERBISON GP, TAYLOR DR: Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. (2001) 17:368-373.
   PubMed Web of Science ®Google Scholar
• INMAN MD, O'BYRNE PM: The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. (1996) 153:65-69.
   PubMed Web of Science ®Google Scholar
• RAMAGE L, LIPWORTH BJ, INGRAM CG, CREE IA, DHILLON DP: Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. (1994) 88:363-368.
   PubMed Web of Science ®Google Scholar
• KOROSEC M, NOVAK RD, MYERS E, SKOWRONSKI M, MCFADDEN ER Jr: Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am. J. Med. (1999) 107:209-213.
   PubMed Web of Science ®Google Scholar
• WEINBERGER M, HENDELES L: Theophylline in asthma. N. Engl. J. Med. (1996) 334:1380-1388.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med. (2003) 167:813-818.
   PubMed Web of Science ®Google Scholar
• The American Lung Association Asthma Clinical Research Centers: Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am. J. Respir. Crit. Care Med. (2007) 175:235-242.
   Google Scholar
• EVANS DJ, TAYLOR DA, ZETTERSTROM O, CHUNG KF, O'CONNOR BJ, BARNES PJ: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N. Engl. J. Med. (1997) 337(20):1412-1418.
   PubMed Web of Science ®Google Scholar
• LIM S, JATAKANON A, GORDON D, MACDONALD C, CHUNG KF, BARNES PJ: Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax (2000) 55(10):837-841.
   PubMed Web of Science ®Google Scholar
• SUESSMUTH S, FREIHORST J, GAPPA M: Low-dose theophylline in childhood asthma: a placebo-controlled, double-blind study. Pediatr. Allergy Immunol. (2003) 14:394-400.
   PubMed Web of Science ®Google Scholar
• KELLY K, SPOONER CH, ROWE BH: Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics. Cochrane Database Syst. Rev. (2000), Issue 3. Art. No.: CD002731. DOI: 10.1002/14651858.CD002731.
   Google Scholar
• GUEVARA JP, DUCHARME FM, KEREN R, NIHTIANOVA S, ZORC J: Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst. Rev. (2006), Issue 2. Art. No.: CD003558. DOI: 10.1002/14651858.CD003558.pub2.
   Google Scholar
• VAN DER WOUDEN JC, TASCHE MJA, BERNSEN RMD, UIJEN JHJM, DE JONGSTE JC, DUCHARME FM: Sodium cromoglycate for asthma in children. Cochrane Database Syst. Rev. (2003), Issue 3. Art. No.: CD002173. DOI: 10.1002/14651858.CD002173.
   Google Scholar
• TASCHE MJA, VAN DER WOUDEN JC, UIJEN JHJM et al.: Randomised, placebo-controlled trial of inhaled sodium cromoglycate in 1 – 4-year-old children with moderate asthma. Lancet (1997) 350:1060-1064.
   PubMed Web of Science ®Google Scholar
• DOLOVICH MA, MACINTYRE NR, DHAND R et al.: Consensus conference on aerosols and delivery devices. Respir. Care (2000) 45:588-776.
   Google Scholar
• DONAHUE JG, WEISS ST, LIVINGSTON JM, GOETSCH MA, GREINEDER DK, PLATT R: Inhaled steroids and the risk of hospitalization for asthma. JAMA (1997) 277(11):887-891.
   PubMed Web of Science ®Google Scholar
• CHILDHOOD ASTHMA MANAGEMENT PROGRAM RESEARCH GROUP: Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. (2000) 343:1054-1063.
   Google Scholar
• BASSLER D, MITRA A, DUCHARME FM, FORSTER J, SCHWARZER G: Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database Syst. Rev. (2004), Issue 1. Art No.:CD001384.
   Google Scholar
• DIAMANT Z, BOOT JD, VIRCHOW JC: Summing up 100 years of asthma. Respir. Med. (2007) 101:378-388.
   PubMed Web of Science ®Google Scholar
• SEDDON P, BARA A, DUCHARME FM, LASSERSON TJ: Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst. Rev. (2006), Issue 1. Art No.:CD002885.
   Google Scholar
• WECHSLER ME: Optimal management of asthma: leukotriene modifiers. In: Pharmacotherapy of Asthma. Li JT (Ed.), Taylor and Francis, New York (2006):117-149.
   Google Scholar
• KEAM SJ, LYSENG-WILLIAMSON KA, GOA KL: Pranlukast: a review of its use in the management of asthma. Drugs (2003) 63:991-1019.
   PubMed Web of Science ®Google Scholar
• DUCHARME FM, DI SALVIO F: Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst. Rev. (2004), Issue 1. Art. No.: CD002314. DOI: 10.1002/14651858.CD002314.pub2.
   Google Scholar
• DUCHARME F, SCHWARTZ Z, KAKUMA R: Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. (2004), Issue 1. Art. No.: CD003133. DOI: 10.1002/14651858.CD003133.pub2.
   Google Scholar
• DUCHARME FM, LASSERSON TJ, CATES CJ: Long-acting β2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev. (2006), Issue 4. Art. No.: CD003137. DOI: 10.1002/14651858.CD003137.pub3.
   Google Scholar
• DEYKIN A, WECHSLER ME, BOUSHEY HA et al.: Combination therapy with a long-acting β-agonist and a leukotriene antagonist in moderate asthma. Am. J. Respir. Crit. Care Med. (2007) 175:228-234.
   PubMed Web of Science ®Google Scholar
• SORKNESS CA, LEMANSKE RF, MAUGER DT et al.: Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the pediatric asthma controller trial. J. Allergy Clin. Immunol. (2007) 119:64-72.
   PubMed Web of Science ®Google Scholar
• GARCIA GARCIA ML, WAHN U, GILLES L, SWERN A, TOZZI CA, POLOS P: Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics (2005) 116:360-369.
   PubMed Web of Science ®Google Scholar
• OSTROM NK, DECOTIS BA, LINCOURT WR et al.: Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J. Pediatr. (2005) 147:213-220.
   PubMed Web of Science ®Google Scholar
• PERONI D, BODINI A, DEL GIUDICE MM et al.: Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens. Allergy (2005) 60:206-210.
   PubMed Web of Science ®Google Scholar
• CAFFEY LF, RAISSY HH, MARSHIK P, KELLY HW: A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. Pediatr. Asthma Allergy Immunol. (2005) 18:10-17.
   Google Scholar
• SZEFLER SJ, PHILLIPS BR, MARTINEZ FD et al.: Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. (2005) 115:233-242.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, CHERVINSKY PS, FRIEDMAN B et al.: Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. (2002) 110:847-854.
   PubMed Web of Science ®Google Scholar
• KNORR B, FRANCHI LM, BISGAARD H et al.: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics (2001) 108(3):E48.
   PubMed Web of Science ®Google Scholar
• VAN ADELSBERG J, MOY J, WEI LX, TOZZI CA, KNORR B, REISS TF: Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr. Med. Res. Opin. (2005) 21:971-979.
   PubMed Web of Science ®Google Scholar
• SZEFLER SJ, EIGEN H: Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J. Allergy Clin. Immunol. (2002) 109: 730-742.
   PubMed Web of Science ®Google Scholar
• BISGAARD H, GILLIES J, GROENEWALD M, MADEN C: The effect of inhaled fluticasone propionate in the treatment of young asthmatic children. A dose comparison study. Am. J. Respir. Crit. Care Med. (1999) 160:126-131.
   PubMed Web of Science ®Google Scholar
• BISGAARD H, ZIELEN S, GARCIA-GARCIA ML et al.: Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. (2005) 171(4):315-322.
   PubMed Web of Science ®Google Scholar
• ROBERTSON CF, PRICE D, HENRY R et al.: Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am. J. Respir. Crit. Care Med. (2007) 175:323-329.
   PubMed Web of Science ®Google Scholar
• BUKSTEIN DA, LUSKIN AT, BERNSTEIN A: “Real world” effectiveness of daily controller medicine in children with mild persistent asthma. Ann. Allergy Asthma Immunol. (2003) 90:543-549.
   PubMed Web of Science ®Google Scholar
• CARTER ER, ANANTHAKRISHNAN M: Adherence to montelukast versus inhaled corticosteroids in children with asthma. Pediatr. Pulmonol. (2003) 36:301-304.
   PubMed Web of Science ®Google Scholar
• STEMPEL DA, KRUZIKAS DT, MANJUNATH R: Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast. J. Pediatr. (2007) 150:162-167.
   PubMed Web of Science ®Google Scholar
• LAZARUS SC, CHINCHILLI VM, ROLLINGS NJ et al.: Smoking affects response to a inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am. J. Respir. Crit. Care Med. (2007) 175:783-790.
   PubMed Web of Science ®Google Scholar
• STRUNK RC, BLOOMBERG GR: Omalizumab for asthma. N. Engl. J. Med. (2006) 354:2689-2695.
   PubMed Web of Science ®Google Scholar
• WALKER S, MONTEIL M, PHELAN K, LASSERSON TJ, WALTERS EH: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. (2006), Issue 2. Art. No.: CD003559. DOI: 10.1002/14651858.CD003559.pub3.
   Google Scholar
• HOLGATE ST, CHUCHALIN AG, HEBERT J et al.; Omalizumab 011 International Study Group: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy (2004) 34(4):632-638.
   PubMed Web of Science ®Google Scholar
• AYRES JG, HIGGINS B, CHILVERS ER, AYRE G, BLOGG M, FOX H: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy (2004) 59(7):701-708.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, BEASLEY R, AYRES J et al.: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 60:309-316.
   PubMed Web of Science ®Google Scholar